Patents by Inventor USHA BUGHANI

USHA BUGHANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
    Publication number: 20240101700
    Abstract: The present invention discloses a key mechanism of action of itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 28, 2024
    Inventors: Pradip NAIR, Arindam SAHA, Ravindra Belavinakodige SADASHIVARAO, Usha BUGHANI, Ramakrishnan MELARKODE
  • ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19
    Publication number: 20230151107
    Abstract: The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive immune response, such as the high expression levels of cytokines.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 18, 2023
    Inventors: Pradip NAIR, Jose Enrique Montero CASIMIRO, Kiran MAZUMDARSHAW, Usha BUGHANI, Sandeep Nilkanth ATHALYE, Melarkode Subbaraman RAMAKRISHNAN, Tania CROMBET RAMOS, Kalet LEÓN MONZÓN, Mayra RAMOS SUZARTE
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20220025038
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 27, 2022
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
    Patent number: 11060097
    Abstract: The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 13, 2021
    Inventors: Nagaraj Govindappa, Sreesha P. Srinivasa, Usha Bughani, Reshmi Nair
  • Use of a CD6 binding partner and method based thereon
    Patent number: 11028168
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 8, 2021
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20190345247
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 14, 2019
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
    Publication number: 20190248913
    Abstract: The present invention discloses a key mechanism of action of Itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 15, 2019
    Inventors: Pradip NAIR, Arindam SAHA, Ravindra Belavinakodige SADASHIVARAO, Usha BUGHANI, Ramakrishnan MELARKODE
  • TARGETED/IMMUNOMODULATORY FUSION PROTEINS IN COMBINATION WITH ADDITIONAL THERAPEUTIC AGENTS AND METHODS FOR MAKING SAME
    Publication number: 20190169621
    Abstract: The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Application
    Filed: January 31, 2019
    Publication date: June 6, 2019
    Inventors: NAGARAJ GOVINDAPPA, SREESHA P. SRINIVASA, USHA BUGHANI, RESHMI NAIR
  • Use of a CD6 binding partner and method based thereon
    Patent number: 10189899
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 29, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20160152705
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 2, 2016
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO